Fusobacterium nucleatum host-cell binding and invasion induces IL-8 and CXCL1 secretion that drives colorectal cancer cell migration.

<i>Fusobacterium nucleatum</i> is implicated in the acceleration of colorectal cancer (CRC), yet the mechanisms by which this bacterium modulates the tumor microenvironment remain understudied. Here we show that binding and cellular invasion of CRC cells selectively induces the secretion of the pro-inflammatory and metastatic cytokines IL-8 and CXCL1, which we then show induces robust migration of HCT116 cancer cells. Next, we demonstrate that cytokine signaling by cancer cells is largely driven by invasion coordinated by the surface adhesin Fap2. By contrast, we show that <i>F. nucleatum</i> induced secretion of CCL3, CXCL2, and TNFα cytokines from neutrophils and macrophages is Fap2 independent. Finally, we show that inhibiting <i>F. nucleatum</i> host-cell binding and entry using galactose sugars, neutralizing membrane antibodies, and deletion of the <i>fap2</i> gene, lead to attenuated cytokine secretion and cellular migration. As elevated IL-8 and CXCL1 levels in cancer have been associated with increased metastatic potential and cell seeding, poor prognosis, and enhanced recruitment of tumor-associated macrophages and fibroblasts within tumor microenvironments, these data show that <i>F. nucleatum</i> directly and indirectly modulates immune and cancer cell signaling and migration. In conclusion, as viable <i>F. nucleatum</i> were previously shown to migrate within metastatic CRC cells, we propose that inhibition of host cell binding and invasion, potentially through vaccination or novel galactoside compounds, could be an effective strategy for reducing <i>F. nucleatum</i>-induced signaling that drives metastasis and cancer cell seeding.

SPRY domain-containing protein 7 (SPRYD7) is a barely known protein identified via spatial proteomics as being upregulated in highly metastatic-to-liver KM12SM colorectal cancer (CRC) cells in comparison to its isogenic poorly metastatic KM12C CRC cells. Here, we aimed to analyze SPRYD7's role in CRC via functional proteomics. Through immunohistochemistry, the overexpression of SPRYD7 was observed to be associated with the poor survival of CRC patients and with an aggressive and metastatic phenotype. Stable SPRYD7 overexpression was performed in KM12C and SW480 poorly metastatic CRC cells and in their isogenic highly metastatic-to-liver-KM12SM-and-to-lymph-nodes SW620 CRC cells, respectively. Upon upregulation of SPRYD7, in vitro and in vivo functional assays confirmed a key role of SPRYD7 in the invasion and migration of CRC cells and in liver homing and tumor growth. Additionally, transient siRNA SPRYD7 silencing allowed us to confirm in vitro functional results. Furthermore, SPRYD7 was observed as an inductor of angiogenesis. In addition, the dysregulated SPRYD7-associated proteome and SPRYD7 interactors were elucidated via 10-plex TMT quantitative proteins, immunoproteomics, and bioinformatics. After WB validation, the biological pathways associated with the stable overexpression of SPRYD7 were visualized. In conclusion, it was demonstrated here that SPRYD7 is a novel protein associated with CRC progression and metastasis. Thus, SPRYD7 and its interactors might be of relevance in identifying novel therapeutic targets for advanced CRC.

Decreased Levels of miR-224 and the Passenger Strand of miR-221 Increase MBD2, Suppressing Maspin and Promoting Colorectal Tumor Growth and Metastasis in Mice

Cancer-associated fibroblasts are critical to tumor progression. There exists a dynamic crosstalk between cancer and stromal compartments, which maintains a permissive tumor microenvironment. Extracellular vesicles (EVs) play a significant role in this intercellular communication. Colorectal cancer (CRC) cells can be categorized according to epithelial-mesenchymal transition (EMT) status, and therefore metastatic capacity. We aimed to investigate the effect of EMT on EV-mediated cancer-fibroblast signaling. CRC cell lines (DLD-1, HCT116, SW620 and SW480) were characterized by western blotting to determine EMT status. EVs were isolated from conditioned media by serial centrifugation and validated by transmission electron microscopy, western blotting and nanoparticle tracking analysis. Fluorescently labeled EVs and cells were detected and evaluated by flow cytometry and fluorescence microscopy. Increasing concentrations of EVs from CRC cells were co-cultured with fibroblasts for 24h. Activation/inhibition of signaling pathways was examined by western blotting. EV microRNA (miRNA) profiles were obtained, validated by qPCR and submitted for target and pathway analysis. DLD-1, HCT116 and SW620 cells express E-cadherin and are considered epithelial, whereas SW480 lacks E-cadherin, expresses ZEB-1, and is considered mesenchymal. EVs were spherical, enriched in ALIX, TSG101, CD63 and had a mean diameter of 90nm. EVs from CRC cells were shown to transfer directly to primary ex vivo patient-derived fibroblasts and fibroblast cell lines. Transfer of EVs from epithelial CRC cells abrogated ERK activity in fibroblasts, even at the lowest concentration, and was associated with reduced fibroblast proliferation, whereas EVs from mesenchymal cells had no effect. MiRNA profiling of EVs from epithelial and mesenchymal CRC cells showed a 10-fold upregulation of miR-143-3p in epithelial compared to mesenchymal EVs. MiRNA target analysis and experimental validation show that miR-143-3p directly targets KRAS and HRAS, providing a potential miRNA-orchestrated mechanism of action for the downregulation of fibroblast ERK activity in the tumor microenvironment. Importantly, CRC cellular ERK activity is not reflected in fibroblasts treated with CRC EVs, suggesting that EVs do not directly transmit ERK protein or mRNA. However, miRNAs are the most stable EV cargo, and we show that epithelial but not mesenchymal CRC EVs contain upregulated miRNAs, which target critical components of the ERK pathway. Downregulation of ERK activity has been shown to induce fibroblast senescence, a phenotype linked to cancer progression. We hypothesize that differential regulation occurs because epithelial CRC cells are juxtaposed with fibroblasts in the tumor core, where senescent cancer associated fibroblasts are frequently observed, whereas mesenchymal CRC cells are at the invasive front or in the circulation. Citation Format: Rahul Bhome, Louise M. House, Tilman Sanchez-Elsner, Stephen M. Thirdborough, Emre Sayan, Alex H. Mirnezami. Metastatic and non-metastatic colorectal cancer cells differentially regulate fibroblast cell cycle via extracellular vesicles [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2982. doi:10.1158/1538-7445.AM2017-2982

Tropomodulin-2 (TMOD2) is upregulated in the nuclear compartment of highly liver metastatic colorectal cancer (CRC) cells. Its role in cancer and CRC progression is functionally undefined, despite its analysis in COAD and READ TCGA datasets revealing a correlation between high TMOD2 expression, advanced disease stages, and poorer survival in CRC patients. We aimed here to explore the role of TMOD2 in CRC and liver metastasis using functional proteomics, tumour samples, bioinformatics, and in vitro and in vivo CRC models. Stable overexpression and stable depletion of TMOD2 in isogenic CRC cells revealed its impact on tumorigenic and metastatic properties. TMOD2 overexpression enhanced cell adhesion, anchorage-independent growth, and migration, while stably TMOD2 depletion reduced them. In vivo, TMOD2-overexpressing cells formed larger tumours and enhanced liver colonisation of CRC cells. Clinically, TMOD2 protein levels demonstrated strong discriminatory ability between metastatic and non-metastatic CRC patients. Proteomic analyses allowed the identification of TMOD2-associated proteins involved in cytoskeletal dynamics, secretion, and focal adhesions, with further validation implicating STAG1 and MARCKS as mediators of TMOD2-driven pathways. Our findings demonstrate that TMOD2 plays a role in CRC progression by modulating cytoskeletal dynamics, enhancing cell adhesion and promoting liver metastasis, positioning TMOD2 as a target for therapeutic intervention in CRC.

Colorectal cancer (CRC) is a frequently diagnosed cancer worldwide. Accumulating researches suggested that circular RNA 0007142 (circ_0007142) contributed to the progression and initiation of CRC. However, the molecular mechanism of circ_0007142 in CRC needs further research. Levels of circ_0007142, microRNA-455-5p (miR-455-5p), and serum- and glucocorticoid-induced protein kinase 1 (SGK1) were identified by quantitative real-time PCR. Cell proliferation was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazol-3-ium bromide assay. Flow cytometry assay was used to detect cell apoptosis in SW480 and HCT116 cells. The relative proteins expression was detected by western blot. Cell migration and invasion were evaluated using transwell assay. Moreover, dual-luciferase reporter and RNA immunoprecipitation assays were conducted to determine the relationship between miR-455-5p and circ_0007142 or SGK1. Finally, xenograft tumor model was established to confirm the effect of circ_0007142 on CRC progression in vivo. Circ_0007142 and SGK1 levels were clearly increased, while miR-455-5p level was reduced in CRC tissues and cell lines. Circ_0007142 silencing promoted cell apoptosis and inhibited cell proliferation, migration and invasion, while these effects of circ_0007142 were partially abolished by miR-455-5p inhibitor in CRC cells. Circ_0007142 could sponge miR-455-5p to regulate SGK1 expression. Moreover, the effects of miR-455-5p on cell proliferation, apoptosis, migration and invasion could be partially reversed by SGK1 overexpression. Besides, circ_0007142 knockdown also suppressed the progression of CRC in vivo. Collectively, Circ_0007142/miR-455-5p/SGK1 axis regulated cell proliferation, apoptosis, migration and invasion of CRC cells, providing a probable therapy target for CRC.

The aim of this study was to clarify the role of TCF19 in influencing the malignant progression of colorectal cancer (CRC) by negatively regulating WWC1. Relative expression levels of TCF19 and WWC1 in CRC tissues and cells were detected by quantitative Real-Time Polymerase Chain Reaction (qRT-PCR). The prognosis of CRC patients was assessed by the Kaplan-Meier method. Meanwhile, the correlation between TCF19 and pathological indexes of CRC patients was evaluated. Regulatory effects of TCF19/WWC1 on viability, colony formation ability, and migration in HT29 and HCT-8 cells were evaluated. Finally, rescue experiments were conducted to elucidate a negative feedback loop of TCF19/WWC1 in influencing the progression of CRC. TCF19 was significantly up-regulated in CRC, while WWC1 was down-regulated. High-level TCF19 or low-level WWC1 indicated worse survival of CRC patients. Besides, TCF19 expression level was positively correlated with the occurrence of distant metastasis in CRC. Silence of TCF19 significantly attenuated proliferative and migratory capacities of HT29 cells. However, overexpression of TCF19 yielded the opposite trends in HCT-8 cells. WWC1 expression was negatively regulated by TCF19 in CRC tissues. In addition, knockdown of WWC1 abolished the regulatory effect of TCF19 on CRC cells. TCF19 is closely correlated with the occurrence of distant metastasis and poor prognosis of CRC. Furthermore, it aggravates the malignant progression of CRC via negatively regulating WWC1.

Angiogenesis plays a key role in the tumorigenesis and progression of colorectal cancer (CRC). In this study, we investigated the effect of long noncoding RNA (lncRNA) GAS5 on the angiogenesis, invasion, and metastasis of CRC, and the involvement of the Wnt/β-catenin signaling pathway. CRC tissues and adjacent normal tissues were collected from 52 patients with CRC. GAS5 expression was determined in vivo and in vitro by real-time quantitative polymerase chain reaction (RT-qPCR). Then RT-qPCR and Western blot were used to identify expression of key genes of Wnt/β-catenin signaling pathway. CRC cells with lowest GAS5 expression were selected and subjected to si-GAS5, oe-GAS5, or XAV939 to validate the effect of GAS5 and Wnt/β-catenin signaling pathway on CRC cell activities. The activation of Wnt/β-catenin signaling pathway was determined in response to GAS5. Subcutaneous tumor growth and microvascular density were observed in nude mice, in which in vivo metastasis was observed following tail vein injection of CRC cells. Initially, poor expression of GAS5 was observed in CRC tissues and cells. Upregulated GAS5 repressed CRC cell invasion and migration in vitro, as well as subcutaneous tumor growth, angiogenesis, and liver metastases in vivo. Furthermore, the Wnt/β-catenin signaling pathway was determined to be activated in CRC tissues and cells, while its activation was inhibited by GAS5. The Wnt/β-catenin signaling pathway promoted the CRC cell invasion and migration in vitro, subcutaneous tumor growth, angiogenesis and, liver metastases in vivo. Taken together, the results of the study conclude that lncRNA GAS5 inhibited the activation of the Wnt/β-catenin signaling pathway, thereby suppressing the angiogenesis, invasion, and metastasis of CRC.

Long non-coding RNA Linc00675 suppresses cell proliferation and metastasis in colorectal cancer via acting on miR-942 and Wnt/β-catenin signaling

Astragaloside IV inhibits colorectal cancer metastasis by reducing extracellular vesicles release and suppressing M2-type TAMs activation

Background MicroRNAs (miRNAs) are an important class of functional regulators involved in human cancers development, including colorectal cancer (CRC). Exploring aberrantly expressed miRNAs may provide us with new insights into the initiation and development of CRC by functioning as oncogenes or tumour suppressors. The aim of our study is to discover the expression pattern of miR-1249 in CRC and investigate its clinical significance as well as a biological role in CRC progression. Methods QRT-PCR was used to detect the relative expression of miR-1249 in CRC tissues and cell lines. EdU, CCK-8, Wound healing, transwell and HUVECs tube formation assays were performed to assess the effect of miR-1249 on CRC cell proliferation, migration, invasion and angiogenesis in vitro, nude mouse xenograft, tail vein injection and chicken chorioallantoic membrane(CAM) model were used to observe CRC growth, metastasis and angiogenesis in vivo. Luciferase reporter assay, western blot, immunohistochemistry(IHC) and immunofluorescence(IF) staining were fulfilled to explore the molecular mechanism of miR-1249 in CRC. Results MiR-1249 was found to be markedly downregulated in CRC tissues and cell lines. The expression of miR-1249 was negatively related to pN stage, pM stage, TNM stage and overall survival(OS). Moreover, we found that miR-1249 was a direct transcriptional target of P53 and revealed that P53-induced miR-1249 inhibited tumour growth, metastasis and angiogenesis in vitro and vivo. Additionally, we verified that miR-1249 suppressed CRC proliferation and angiogenesis by targeting VEGFA as well as inhibited CRC metastasis by targeting VEGFA and HMGA2. Further studying showed that miR-1249 suppressed CRC cell proliferation, migration, invasion and angiogenesis via VEGFA-mediated Akt/mTOR pathway as well as inhibited EMT process of CRC cells by targeting VEGFA and HMGA2. Conclusions Our study demonstrated that P53-induced miR-1249 might suppress CRC growth, metastasis and angiogenesis by targeting VEGFA and HMGA2, as well as regulate Akt/mTOR pathway and EMT process in the initiation and development of CRC. miR-1249 might be a novel the therapeutic candidate target in CRC treatment.

ARHGAP9 inhibits colorectal cancer cell proliferation, invasion and EMT via targeting PI3K/AKT/mTOR signaling pathway

Harnessing Tissue Engineering Tools to Interrogate Host-Microbiota Crosstalk in Cancer.

Colorectal cancer (CRC) development is closely associated with the accumulation of both genetic and epigenetic alterations. Many efforts have been made to investigate the role of epigenetic modifications in CRC metastasis. In this work, we present the quantitative top-down proteomics study focusing on histone proteoforms between metastatic (SW620) and nonmetastatic (SW480) CRC cells to reveal potentially critical histone proteoforms in CRC metastasis. We isolated histone proteins from CRC cells, fractionated them by sodium dodecyl-sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE), and analyzed them by capillary zone electrophoresis (CZE)-tandem mass spectrometry (MS/MS). A total of 230 histone proteoforms were quantified in SW480 and SW620 cell lines, among which 34 proteoforms were significantly altered in abundance in the metastatic cells, indicating a significant transformation of histone proteoforms during metastasis. We observed a significant increase in abundance of all nine differentially expressed histone H4 proteoforms in metastatic SW620 cells compared to SW480 cells, while differentially expressed proteoforms of other histone proteins display diversified expression patterns. Additionally, two histone H2A proteoforms with a combination of N-terminal acetylation and phosphorylation were upregulated in the metastatic CRC cells. These differentially expressed histone proteoforms could be novel proteoform biomarkers of CRC metastasis.

NT5DC2 knockdown inhibits colorectal carcinoma progression by repressing metastasis, angiogenesis and tumor-associated macrophage recruitment: A mechanism involving VEGF signaling